Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5614736 | Journal of Cardiology | 2017 | 7 Pages |
Abstract
This study is a prospective randomized open-label blinded endpoint study. Patient enrolment was started in November 2013 and was completed in October 2014. The patients will be followed for at least 3 years. The primary endpoint is a composite of cerebral, cardiovascular, and renal events, and all deaths including death due to cerebral, cardiovascular, and renal disease, new or recurring cerebrovascular disease, new or recurring non-fatal coronary artery disease, cardiac failure requiring hospitalization, arteriosclerotic disease requiring treatment, renal impairment, new atrial fibrillation, and all deaths other than cerebral or cardiovascular or renal disease. These events will be independently evaluated by the Event Assessment Committee under blinded information regarding the treatment group. The study was registered at ClinicalTrials.gov with the identifier NCT01984749.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sunao MD, PhD, FJCC, Kunihiko MD, PhD, Hisao MD, PhD, FJCC, Hideaki MD, PhD, Shinya MD, Takahiro MD, PhD, FJCC, Naoto MD, PhD, Naoki MD, Eiichi MD, Kazuaki MD, PhD, Masahiro MD, PhD, Hirokazu MD, Yutaka MD, Hisao MD, PhD, Ichiro MD, PhD, FJCC, Masako MD,